Chemotherapy Induced Peripheral Neuropathy (CIPN)
Chemotherapy Induced Peripheral Neuropathy (CIPN) Market

Chemotherapy-Induced Peripheral Neuropathy is a frequent, dose-dependent complication of anticancer drugs, including platinum, taxanes, epothilones, vinca alkaloids, and newer agents.


Chemotherapy-Induced Peripheral Neuropathy Epidemiological Segmentation

The Epidemiological Segmentation of Chemotherapy-Induced Peripheral Neuropathy in 7MM from 2018 to 2030 is segmented as:-

  • Total Incident Population of Chemotherapy-Induced Peripheral Neuropathy
  • Incident Population of CIPN by Chemotherapeutic Agents
  • Severity Specific Incidence of Chemotherapy-Induced Peripheral Neuropathy
  • Incident Population of CIPN by Cancer Type 


Chemotherapy-Induced Peripheral Neuropathy Epidemiology

  • The total prevalent population of Chemotherapy-Induced Peripheral Neuropathy in 7MM in 2018 was 1,522,437
  • The total number of CIPN prevalent cases in the United States was found to be 635,154.
  • Germany had a total of 170,283 Chemotherapy-Induced Peripheral Neuropathy cases.
  • The total number of CIPN cases in the United Kingdom was estimated to be 126,282.
  • The total Chemotherapy-Induced Peripheral Neuropathy prevalent cases in Spain were 76,599.
  • In Japan, the total number of CIPN prevalent cases was observed to be 270,556.


Chemotherapy-Induced Peripheral Neuropathy Market

The therapeutic market size of Chemotherapy-Induced Peripheral Neuropathy in 7MM in 2020 was USD 1,435.67 million.


Chemotherapy-Induced Peripheral Neuropathy Market Drivers

  • Increasing emerging therapies
  • Increasing awareness


Chemotherapy-Induced Peripheral Neuropathy Market Barriers

  • No standard assessment
  • Current therapy limitations
  • Herbal remedies
  • Clinical understanding 


Chemotherapy-Induced Peripheral Neuropathy Emerging Drugs

The emerging drugs of the CIPN market are:

  • SP-04 (PledOx)
  • Tetrodotoxin or TTX
  • E-52862
  • ART-123 (Thrombomodulin alfa)
  • MN-166 (Ibudilast)
  • KRN 5500
  • Niagen
  • TRK-750

and many others.


´╗┐Chemotherapy-Induced Peripheral Neuropathy Key Players

The key players in the CIPN market are:

  • Solasia/PledPharma
  • WEX Pharmaceuticals
  • Laboratorios Dr. Esteve S.A. (ESTEVE)
  • Asahi Kasei Pharma
  • MediciNova
  • DARA BioSciences
  • ChromaDex
  • Toray Industries 

and many others.